Clinical trials: Immediate Hypersensitivity
Asthma
A Study to Evaluate the Pharmacokinetics of MEDI9929 (AMG 157) in Adolescents With Mild to Moderate Asthma
To evaluate the PK profile of a single-dose of 140 mg subcutaneous (SC) administration of MEDI9929 (AMG 157) in adolescent subjects with mild to moderate asthma.
- Trial name
- NCT02512900
- Testing
- MEDI9929, 140 mg
- Where
- 4 sites in Poland
- Volunteers
- 21 people
- Sponsor
- MedImmune LLC
Asthma
Fenzian Asthma Multicenter Outcomes Study
The purpose of this study is to investigate the effects of Fenzian™ treatment on symptoms (such as shortness of breath), lung function (how well the lungs work), and albuterol/salbutamol (rescue medication) use in people with…
- Trial name
- FAMOUS (NCT00784758)
- Testing
- Fenzian Device
- Where
- 6 sites in United States, South Africa and 1 more
- Volunteers
- 81 people
- Sponsor
- University of California, Los Angeles
Asthma
Study of MK-1029 in Participants With Persistent Asthma That Cannot Be Controlled With Montelukast (MK-1029-015)
The purpose of this trial is to compare the safety, tolerability, and efficacy of adding MK-1029 to montelukast in adults with persistent asthma that is uncontrolled while receiving montelukast alone.
- Trial name
- NCT02720081
- Testing
- MK-1029 150 mg, Montelukast 10 mg, Albuterol/Salbutamol 90 mcg - 100 mcg per inhalation
- Volunteers
- 142 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Spontaneous Urticaria
A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines
The purpose of this study was to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) in adult participants suffering from chronic spontaneous urticaria (CSU) inadequately controlled by H1-antihistamines in…
- Trial name
- REMIX-1 (NCT05030311)
- Testing
- LOU064 25 mg (b.i.d), LOU064 25 mg (b.i.d) as a tablet.
- Where
- 112 sites in United States, Argentina and 17 more
- Volunteers
- 470 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma
The overall purpose of the trial is to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 mcg and 5 mcg once daily in the evening) over 48 weeks, compared to placebo, in children…
- Trial name
- NCT01634139
- Testing
- Tiotropium low dose QD, Tiotropium high dose QD
- Where
- 79 sites in United States, Bulgaria and 14 more
- Volunteers
- 403 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component
The purpose of this study is to evaluate the dose-response of 4 doses of umeclidinium bromide in combination with fluticasone furoate compared with fluticasone furoate monotherapy in chronic obstructive pulmonary disease…
- Trial name
- NCT02164539
- Testing
- FF, UMEC, VI
- Where
- 67 sites in United States, Argentina and 5 more
- Volunteers
- 338 people
- Sponsor
- GlaxoSmithKline
Asthma, Bronchospasm
Epinephrine Inhalation Aerosol USP, a HFA-MDI Study for Assessment of Pharmacokinetics
This study examines the pharmacokinetic profile of Armstrong's proposed Epinephrine Inhalation Aerosol USP, an HFA-MDI (E004), using a stable isotope deuterium-labeled epinephrine (epinephrine-d3) to differentiate the…
- Conditions
- Asthma, Bronchospasm, Wheezing, Shortness of Breath
- Trial name
- NCT01188577
- Testing
- Epinephrine Inhalation Aerosol, HFA, Epinephrine Inhalation Aerosol
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Perennial Allergic Rhinitis
NasoNeb Delivery of an Intranasal Steroid
The purpose of this study is to see if a nasal steroid drug delivered to the nose with the NasoNeb™ inhaler improves the symptoms of people with perennial allergic rhinitis (year round allergy symptoms).
- Trial name
- NCT01270256
- Testing
- Budesonide
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Chicago
Asthma
Using Technology-Assisted Stepped Care Intervention to Improve Adherence in Adolescents With Asthma
To test the preliminary efficacy of the TASC adherence promotion intervention for adolescents with asthma in a feasibility randomized controlled trial compared to treatment as usual control arm.
- Trial name
- TASC (NCT04365556)
- Testing
- TASC Intervention
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Chronic Spontaneous Urticaria
Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)
Primary Objective: This study aimed to demonstrate the efficacy of dupilumab in study participants with CSU who remained symptomatic despite the use of H1 antihistamine (Study A and C: omalizumab naïve; Study B: omalizumab…
- Trial name
- NCT04180488
- Testing
- Dupilumab SAR231893, non sedating H1-antihistamine
- Where
- 98 sites in United States, Argentina and 9 more
- Volunteers
- 397 people
- Sponsor
- Sanofi
Chronic Spontaneous Urticaria
A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous lirentelimab (AK002) in adult subjects with H-1 antihistamine refractory chronic spontaneous…
- Trial name
- MAVERICK (NCT05528861)
- Testing
- Lirentelimab (AK002)
- Where
- 67 sites in United States, Germany and 1 more
- Volunteers
- 127 people
- Sponsor
- Allakos Inc.
Seasonal Allergic Rhinitis
A Study Investigating the Effect of Montelukast in Patients With Seasonal Allergic Rhinitis (MK-0476-192)(COMPLETED)
A study of the ability of montelukast to improve signs and symptoms of seasonal allergic rhinitis compared with placebo. Loratadine is included in the study as an active control.
- Trial name
- NCT00960141
- Testing
- montelukast sodium, Comparator: loratadine
- Volunteers
- 829 people
- Sponsor
- Organon and Co
Asthma
A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype
This study will assess the efficacy and safety of GSK3511294 (Depemokimab) as an adjunctive therapy in participants with severe uncontrolled asthma with an eosinophilic phenotype.
- Trial name
- SWIFT-2 (NCT04718103)
- Testing
- GSK3511294
- Where
- 129 sites in United States, Australia and 9 more
- Volunteers
- 397 people
- Sponsor
- GlaxoSmithKline
Milk Hypersensitivity
Milk Oral Immunotherapy in Children to Treat Food Allergy
Background and Rationale For patients with Immunoglobulin E (IgE)-mediated food allergy, the current management includes identification of the causative food and avoidance.
- Trial name
- NCT01162473
- Testing
- Milk Oral Immunotherapy, Milk Protein Powder, Food Challenge
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Children's Hospital of Philadelphia
Atopic Dermatitis
Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis
This is a research study to determine the efficacy and safety of investigational drug MEDI3506 for the treatment of adult subjects with Atopic Dermatitis.
- Trial name
- NCT04212169
- Testing
- MEDI3506
- Where
- 38 sites in United States, Australia and 4 more
- Volunteers
- 148 people
- Sponsor
- AstraZeneca
Eczema, Dermatitis
Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Eczema/Dermatitis and Dermal Pruritus (MK-4117-202)
This is an efficacy and safety study of up to 12 weeks of desloratadine in Japanese participants with eczema/dermatitis and dermal pruritus.
- Conditions
- Eczema, Dermatitis, Dermal Pruritus
- Trial name
- NCT01916980
- Testing
- Desloratadine 5 mg
- Volunteers
- 94 people
- Sponsor
- Organon and Co
Asthma
Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma
This study will assess the change in the expression of FcεRI receptors of blood basophils and dendritic cells after 16 weeks of treatment with omalizumab as compared with placebo, in adult patients with non-atopic severe…
- Trial name
- NATAIR (NCT01007149)
- Testing
- omalizumab
- Where
- 10 sites in France
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma.
This is a Phase III, multicenter, randomized, double-blind, stratified, parallel-group study with three active comparators in subjects with moderate to severe persistent asthma.
- Trial name
- NCT01686633
- Testing
- Fluticasone Furoate/ Vilanterol 200/25 mcg, Fluticasone Furoate/ Vilanterol 100/25 mcg, Fluticasone Furoate 100 mcg
- Where
- 136 sites in United States, Argentina and 9 more
- Volunteers
- 1,040 people
- Sponsor
- GlaxoSmithKline
Asthma
Repeat Dose Study of GSK3772847 in Participants With Moderate to Severe Asthma With Allergic Fungal Airway Disease (AFAD)
This study is multicenter, double-blinded parallel group design, where participants with moderate to severe asthma with AFAD will be enrolled.
- Trial name
- NCT03393806
- Testing
- GSK3772847
- Where
- 18 sites in France, Netherlands and 2 more
- Volunteers
- 17 people
- Sponsor
- GlaxoSmithKline
Asthma
TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER)
Evaluate the superiority of CHF 5993 200/6/12.5 µg pressurised metered dose inhaler (pMDI) (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate plus glycopyrronium bromide) versus CHF 1535 200/6 µg…
- Trial name
- TRIGGER (NCT02676089)
- Testing
- CHF 5993 200/6/12.5 µg, CHF 1535 200/6 µg, CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg
- Where
- 244 sites in Argentina, Belarus and 15 more
- Volunteers
- 1,437 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.